iOnctura, a spin-off from Merck, is a clinical stage biopharmaceutical company dedicated to delivering innovative cancer treatments to patients with unmet medical need.
iOnctura is leading the development of precision drugs that simultaneously target multiple tumor survival pathways
iOnctura was founded in 2017 by Catherine Pickering, as a spin-out from Merck. The company is headquartered in Geneva, Switzerland, with an office in Amsterdam, Netherlands.
iOnctura is developing a pipeline of best in class molecules that harness the combined effect of immune-mediated and direct anti-tumour activity with an aim to deliver molecules with superior clinical efficacy and safety in oncology.
iOnctura has progressed two therapeutic candidates into mid-stage clinical development: IOA-244, a highly selective allosteric inhibitor of PI3Kδ; and IOA-289, a highly-selective, non-competitive autotaxin (ATX) inhibitor.
iOnctura is backed by European Investment Council's (EIC) Accelerator, M Ventures, Schroders Capital, Inkef Capital, 3B Future Health Fund, VI Partners, and others. The company secured €17.5M in new financing (consists of a €2.5M Grant and €15M in equity) on Dec 20, 2022. This brings iOnctura's total funding to €39.6M to date.